Maxcyte Appoints Two New Non-Executive Directors

RNS Number : 8666B
MaxCyte, Inc.
15 June 2021




MaxCyte Adds Two New Non-Executive Directors to Its Board


Gaithersburg, Maryland - 15 June 2021: MaxCyte (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, today announced the appointment of Rekha Hemrajani and Yasir Al-Wakeel, BM BCh, to the company's board of directors as non-executive directors with immediate effect. Ms. Hemrajani is appointed as a non-executive member of the Compensation Committee and Dr. Al-Wakeel is appointed as a non-executive member of the Audit Committee. 


"With their expertise in business and corporate development as well as finance combined with deep life sciences industry experience, Ms. Hemrajani and Dr. Al-Wakeel bring valuable insights and perspective to our board," said Doug Doerfler, president and CEO of MaxCyte. "We are honored to have them join us as we advance the next-generation of cell therapy discovery, development and commercialisation."


Ms. Hemrajani is a senior executive with more than 20 years of biopharmaceutical industry experience and has extensive expertise in all aspects of corporate strategy, corporate and business development, financing, and strategic planning. She currently serves as chief executive officer (part time) and director of Jiya Acquisition Corp (NASDAQ: JYAC), where she led the $100 million initial public offering (IPO). Ms. Hemrajani has held senior management positions at numerous listed biopharmaceutical companies, including president, chief executive officer and director of Aravive, Inc (NASDAQ: ARAV),  chief financial officer and chief operating officer of Arcus Biosciences, Inc. (NYSE: RCUS), and chief operating officer of FLX Bio, Inc. (NASDAQ: RAPT). Previously, she was vice president, head of Licensing and Mergers & Acquisitions Group for Onyx Pharmaceuticals (NASDAQ: ONXX sold to Amgen for $10.4 billion), vice president of business development of Exelixis (NASDAQ: EXEL), and on the healthcare investment banking teams of Lehman Brothers, Inc. and Credit Suisse First Boston.  She is currently a non-executive director of ALX Oncology Holdings (NASDAQ: ALXO).


Ms. Hemrajani received a Master of Management from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.S. in economics and computer science from the University of Michigan.


Dr. Al-Wakeel currently serves as chief financial officer and head of corporate development for Kronos Bio (NASDAQ: KRON), where he oversees the company's financial planning and accounting, investor relations, and business development activities.  He was instrumental in the company's $288 million IPO. He previously served as chief financial and strategy Officer at Neon Therapeutics (NASDAQ: NTGN) where he played a key role in the company's public and private financings as well as its eventual sale to BioNTech. Prior to that, he was chief financial officer and head of corporate development at Merrimack Pharmaceuticals (NASDAQ: MACK), where he helped shape and execute the company's refocused business strategy, culminating in a $1 billion asset sale to Ipsen. Prior to those roles, Dr. Al-Wakeel served in senior roles in equity research and corporate finance at Credit Suisse focused on the biotechnology sector. During his tenure in corporate finance, he was involved in more than $30 billion in strategic and financial transactions for the firm.


Dr. Al-Wakeel, began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom. He holds a BM BCh (Doctor of Medicine and Surgery) from Oxford University and an M.A. in theology from Cambridge University.


Grant of options


As is customary for US companies, upon appointment, Ms. Hemrajani and Dr. Al-Wakeel have each been granted 80,700 options over common stock,  $0.01 par, of the Company ("Options"). These Options vest over three (3) years, with initial vesting of 1/3rd of the total after twelve (12) months, and the remainder vesting monthly over the following twenty-four (24) months. The Options have an exercise price of £8.92, equal to the closing price of Maxcyte's stock on 14 June 2021.


Ms. Hemrajani, 52, is, or has been in the previous five years, a director or partner of the following companies:


Current appointment

Past appointment

Jiya Acquisition Corp

Aravive, Inc

ALX Oncology Holdings Inc

Adverum Biotechnologies, Inc

Ravinia Consulting Inc

Hemmo Pharma LLP

Hemmo Pharmaceuticals Private Limited

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.


Dr. Al-Wakeel, 39, is, or has been in the previous five years, a director or partner of the following companies:


Current appointment

Past appointment

Taha Collective, Inc

Boston Life Sciences, LLC


The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.




Details of the person discharging managerial responsibilities/person closely associated



Rekha Hemrajani

Yasir Al-Wakeel


Reason for the notification



Non-Executive Directors


Initial notification/Amendment

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



MaxCyte, Inc.





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

 Options over common stock ,  $0.01 par, of the Company


Identification Code



Nature of the transaction

Grant of Options


Price(s) and volume(s)

Rekha Hemrajani - 80,700 Options at an exercise price of £8.92

Yasir Al-Wakeel - 80,700 Options at an exercise price of £8.92


Aggregated information

- Aggregated volume

- Price





Date of the transaction

14 June 2021


Place of the transaction

London Stock Exchange, AIM Market (XLON)



About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialisation. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centres focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted pre-clinical and clinical licences to academic and industry customers covering over an estimated 140 programmes, of which an estimated 100 programmes are for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit .


For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer


+1 301 944 1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon 

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden


+44 (0)20 7886 2500

 Joint Corporate Broker

Numis Securities Limited

James Black / Duncan Monteith / Matthew O'Dowd


+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams  


+44 (0) 20 7710 7600

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh


+ 44 (0)203 709 5700




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100